All In Biotech

Drug Trial Radar · NCT04221035

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Nov 5, 2019

Primary completion

Nov 2026

Study completion Nov 2032

Sponsor

Lead sponsor
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.

Conditions

  • High-Risk Neuroblastoma
  • Patient With Insufficient Response Chemoimmunotherapy

Interventions

  • VincristineDrug

    1.5 mg/m2 (max dose 2 mg)

  • CarboplatinDrug

    750 mg/m2

  • EtoposideDrug

    175 mg/m2

  • VindesineDrug

    3 mg/m2/day (max dose 6 mg)

  • DacarbazineDrug

    200 mg/m2/day

  • IfosfamideDrug

    1500 mg/m2/day

  • DoxorubicinDrug

    30 mg/m2/dose

  • BusulfanDrug

    \< 9kg: 1.0 mg/kg/dose 9 kg to \< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose \>23 kg to 34 kg: 0.95 mg/kg/dose \>34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses

  • MelphalanDrug

    140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose

  • ThiotepaDrug

    300 mg/m2/day over 2 hours

  • RadiotherapyRadiation

    21.6 Gy 21.6 Gy + boost de 14.4 Gy

  • Dinutuximab BetaDrug

    Patients \>12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day

  • CisplatinDrug

    80 mg/m2/24h

  • Temozolomide 100 MGDrug

    100 mg/m²/Day

  • IrinotecanDrug

    50 mg/m²/jour de J0 à J4

  • CyclophosphamidDrug

    Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event free survival (EFS)Time frame: Assessed at each end of randomization sequences up to one year

Locations

142 sites in 20 countries. Site status is shown where the registry gives one.

  • Children's Cancer Centre, Monash Children's Hospital

    Clayton, Australia · Recruiting

  • Oncology/Haematology Department, Perth Children's Hospital

    Nedlands, Australia · Suspended

  • Children's Cancer & Haematology Services, John Hunter Children's Hospital

    New Lambton Heights, Australia · Recruiting

  • Australian and New Zealand Children's Hematology/oncology Group

    Sydney, Australia · Active not recruiting

  • sydney children Hospital

    Sydney, Australia · Recruiting

  • Cancer Centre for Children, The Children's Hospital

    Westmead, Australia · Suspended

  • Sydney children Hospital

    Sydney, Randwick, Australia · Recruiting

  • Medical University Graz

    Graz, Austria · Recruiting

  • Landeskrankenhaus-Universitätsklinikum Innsbruck

    Innsbruck, Austria · Recruiting

  • Kepler Universitatsklinikum Linz

    Linz, Austria · Recruiting

  • Universitastsklinikum Salzburg

    Salzburg, Austria · Recruiting

  • St Anna'S Children Hospital

    Vienna, Austria · Recruiting

  • Hôpital Universitaire des Enfants Reine Fabiola (ULB)

    Brussels, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc (UCL)

    Brussels, Belgium · Recruiting

  • University Hospital Gent

    Ghent, Belgium · Recruiting

  • University Hospitals Leuven

    Leuven, Belgium · Recruiting

  • CHR Citadelle

    Liège, Belgium · Recruiting

  • Klinika dětské onkologie FN Brno

    Brno, Czechia · Not yet recruiting

  • University Hospital Motol

    Prague, Prague, Czechia · Recruiting

  • Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • Department of Paediatrics and Adolescent Medicine, Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • The Hans Christian Andersen Children's Hospital, University of Southern Denmark

    Odense, Denmark · Recruiting

  • New Children's Hospital, Helsinki University Hospital, Helsinki and Uusimaa Hospital District

    Helsinki, Finland · Not yet recruiting

  • Kuopio University Hospital

    Kuopio, Finland · Not yet recruiting

  • Oulu University Hospital

    Oulu, Finland · Not yet recruiting

  • Tampere University Hospital

    Tampere, Finland · Not yet recruiting

  • Turku University Hospital

    Turku, Finland · Not yet recruiting

  • CHU d'AMIENS

    Amiens, France · Recruiting

  • CHU angers

    Angers, France · Recruiting

  • CHU-Pôle Médico-Chirurgical de l'Enfant et l'Adolescant

    Besançon, France · Recruiting

  • CHU Bordeaux

    Bordeaux, France · Recruiting

  • Groupe Hospitalier Pellegrin - Chu - Bordeaux

    Bordeaux, France · Recruiting

  • CHU Brest

    Brest, France · Recruiting

  • CHU Brest - Hôpital du Morvan

    Brest, France · Recruiting

  • Centre François Baclesse

    Caen, France · Active not recruiting

  • CHU de Caen

    Caen, France · Recruiting

  • CHU Estaing

    Clermont-Ferrand, France · Recruiting

  • Centre Georges-François Leclerc

    Dijon, France · Active not recruiting

  • Hopital d'enfants Marechal de lattre

    Dijon, France · Recruiting

  • Hôpital Couple-Enfant CHU de Grenoble

    Grenoble, France · Recruiting

Showing 40 of 142 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.